BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 08, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Telatinib: Phase I data

A dose-escalation, European Phase I trial in 39 patients with refractory colorectal cancer showed that twice-daily >=600 mg oral telatinib led to tumor shrinkage in 41% of patients, plus 22 cases of stable disease. Telatinib was well...

Read the full 163 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >